Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high262.00 04/10/16
52 week low88.00 16/09/16
52 week change 70.00 (65.12%)
4 week volume1,082,395 28/03/17

Media for (SUMM)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Summit Therapeutics plc : Grant of Share Options

Summit Therapeutics plc: Grant of Share Options Summit Therapeutics plc ("Summit", the "Company", or the "Group") GRANT OF SHARE OPTIONS TO DIRECTORS/PDMRS Oxford, UK, 12 April 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystro...

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 10 April 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces ...

Summit Therapeutics File US Annual Report on Form 20-F

Summit Therapeutics File US Annual Report on Form 20-F Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS FILES US ANNUAL REPORT ON FORM 20-F Oxford, UK, 31 March 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne ...

Summit changes registered office

Summit Therapeutics has announced that the Company's registered office has changed to 136a Eastern Avenue, Milton Par...

Summit Therapeutics plc : Change of Registered Office

Summit Therapeutics plc: Change of Registered Office Summit Therapeutics plc ('Summit', 'the Company') SUMMIT ANNOUNCES CHANGE OF REGISTERED COMPANY ADDRESS Oxford, UK, 30 March 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscul...

Summit Therapeutics to Present at the Needham Healthcare Conference

Summit Therapeutics to Present at the Needham Healthcare Conference Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PRESENT AT THE NEEDHAM HEALTHCARE CONFERENCE Oxford, UK, 30 March 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and developm...

Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress

Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED 31 JANUARY 2017 AND OPERATIONAL PROGRESS Conference Ca...

Summit schedules FY results

Summit Therapeutics will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2017...

Fundamental DataMore

EPS-44
Dividend yield0 %

Latest discussion posts More

  • Final results out

    DMD drug trial update Q1 2018. Cdif drug Phase 3 to start Q1 2018. High cash burn. May get more up front from Sarepta 2017. DYOR
    29-Mar-2017
    bobsson
  • NEW ARTICLE: Trends and Targets for 6/03/2017

    " FTSE FOR THE WEEK (FTSE:UKX)A Friday was irritating. It's one thing to speculate "all the action will happen at the open", quite another to glance at the FTSE at 8:01am ...
    5-Mar-2017
    II Editor
  • RNS Ridinilazole CDI

    Good RNS today to push sp up around 13% to #1.90. The FDA and EMA have agreed with Summit the parameters for the Phase 3 trials. Essentially the authorities want the Phase 3 ...
    1-Feb-2017
    bobsson

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
LLOYDS GRP.21%
RANGE RES.19%
ROYAL BANK SCOT15%
SIRIUS MINERALS15%
ROCKHOPPER12%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM